Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
Amanda Lopez(University of Pennsylvania), Michael Kluk(Cornell University), Gail J. Roboz(Cornell University), Sanjay S. Patel(Brigham and Women's Hospital), Paul D. Simonson(Cornell University), Julia T. Geyer(Cornell University), Nuria Mencia-Trinchant(NewYork–Presbyterian Hospital), Giorgio Inghirami(Cornell University), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Alexandra Gomez-Arteaga(Cornell University), Amy Chadburn(Cornell University), Wayne Tam(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Sangmin Lee(Janssen (United States)), Madhu M. Ouseph(The Ohio State University), Joelle Racchumi(NewYork–Presbyterian Hospital)
Cited by 19
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k